Clinical Trials Logo
  1. Home
  2. Avascular Necrosis
  3. NCT00412841

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus

Avascular Necrosis Clinical Trial

Official title:
AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial

Clinical Trial Summary

This study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a disease resulting from the loss of blood supply to the bones which can cause the bone to collapse. The collapse of bone may require a surgical replacement of the joint and can be disabling for life. Avascular necrosis is presently not preventable but research has shown that lipid lowering drugs such as lipitor can reduce or prevent avascular necrosis in animals. We therefore hypothesize that lipitor will reduce the incidence of avascular necrosis in lupus patients taking high dose steroids.

Clinical Trial Description

If you have started on prednisone 30mg or greater and expect to be on it for greater than two weeks you may be a candidate for the study. Also, you would need to be enrolled in the study within three days of starting prednisone. If you are eligible you will receive lipitor 40mg per day or pills which look exactly like lipitor but do not contain any medication (called placebo). During the time of the study, you will not know if you are taking lipitor or the placebo. The period of time that you will receive lipitor or placebo is 9 months and you must be willing to return for 5 follow up visits during this time which include blood tests, physical exams and 3 MRI studies of the hips, knees and ankles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00412841
Study type Interventional
Source New York University School of Medicine
Contact
Status Terminated
Phase Phase 2
Start date November 2002
Completion date January 2008
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03312465 - Anatomical Shoulder Domelock System Study
Completed NCT02139345 - TC-A Registration Study N/A
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Completed NCT01285843 - Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component N/A
Completed NCT00750984 - A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing N/A
Active, not recruiting NCT00175487 - Comparison of Hip Resurfacing to Large Femoral Head Total Hip Arthroplasty N/A
Terminated NCT00872547 - Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement Phase 4
Completed NCT00603395 - A Prospective Clinical Study On A Total Hip Resurfacing System N/A
Recruiting NCT02503891 - AL-2 MP-1 (Polyimide) Acetabular Liner N/A
Completed NCT03666637 - Femoral Neck Fracture in Adult and Avascular Necrosis and Nonunion
Active, not recruiting NCT03343171 - Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study
Enrolling by invitation NCT05067543 - Perform Humeral System Study
Recruiting NCT05002335 - Clinical and Radiological Outcomes of Medacta Shoulder System (BE)
Active, not recruiting NCT03423953 - Comprehensive Nano - Post Market Clinical Follow-Up Study
Active, not recruiting NCT05049993 - Pyrocarbon Clinical Follow-up Study
Completed NCT02162186 - Clinical and Radiographic Outcomes of the Corin Tri-Fit Total Hip Replacement
Active, not recruiting NCT01700543 - Sidus(TM) Post Market Clinical Follow-up (PMCF) Study
Active, not recruiting NCT02199600 - The Medacta International GMK Sphere Post-Marketing Surveillance Study N/A
Not yet recruiting NCT01437124 - Metal Ions in Ceramic on Metal Total Hip Arthroplasty N/A
Terminated NCT00764959 - Retrospective Study of the Linear™ Hip Phase 4